Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing

Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing

Reviewed by Emily Henderson, B.Sc.Apr 1 2021

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

The guideline, "PD-L1 Testing of Patients With Lung Cancer for Immunooncology Therapies," includes a draft summary of six recommendations, which is now available for an open comment period from March 31 to April 23, 2021.

All stakeholders-;including pathologists, oncologists, hospital or laboratory managers, and patient advocacy group representatives-;are encouraged to review and submit feedback on these draft recommendations.

Given the rapid evolution of immunotherapy and immunomodulatory drugs, pathologists have a need to develop universally accepted, standardized criteria for immunohistochemistry (IHC)-based testing of immune checkpoint proteins, particularly for PD-L1."

Lynette Sholl, MD, FCAP, Project Co-Chair and Pathologist, Brigham and Women's Hospital, Boston

Related Stories

  • Study reveals biomarkers for the prognosis of gastric adenocarcinoma
  • The Dream Team opens clinical trial to find better treatment options for pancreatic cancer
  • Sequential administration of immunotherapy and targeted therapy prolongs anti-tumor responses

Along with Dr. Sholl, co-chair and pathologist Larissa V. Furtado, MD, FCAP, St. Jude Children's Research Hospital, Memphis, lead the guideline development panel, which also includes experts from these collaborating groups: the American Society of Clinical Oncology (ASCO); the Association for Molecular Pathology (AMP); the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS); and LUNGevity Foundation.

"We have also explored evidence to consider tumor mutation burden (TMB), along with or independent of PD-L1 status," Dr. Furtado said. "The burgeoning interest in TMB among clinicians further amplifies the need for unbiased guidance to enable practicing pathologists to make informed testing decisions."

The expert panel will consider all comments garnered during the comment period before finalizing the recommendations and submitting the guideline for publication.


Leave a Reply

Your email address will not be published. Required fields are marked *